Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03030287 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer
A Phase 1 study of Cancer Ovaries and Cancer Peritoneal, sponsored by OncoMed Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 7
- Study locations
NCT03030287: Completed Phase 1 study of Cancer Ovaries and Cancer Peritoneal, sponsored by OncoMed Pharmaceuticals.
NCT03030287 is a Phase 1 study of Cancer Ovaries and Cancer Peritoneal that has completed, run by OncoMed Pharmaceuticals. The registered enrollment target is 44 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (27% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03030287, a Phase 1 study of Cancer Ovaries and Cancer Peritoneal, has completed, sponsored by OncoMed Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to test the efficacy and safety of an experimental drug, OMP-305B83, when given in combination with paclitaxel. OMP-305B83 is a humanized monoclonal antibody and was developed to target cancer stem cells. Based on preclinical studies, it is believed that OMP-305B83 may block the growth of cancer stem cells and may also impair the productive growth of new blood vessels, which tumors need to grow and spread.
Primary Outcome
The maximum tolerated dose (MTD) or maximum administered dose (MAD) will be determined in subjects treated with OMP-305B83 in combination with Paclitaxel
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG OMP-305B83
Study Locations (7)
Colorado
- University of Colorado, Anschutz Medical Campus - Aurora
Florida
- H. Lee Moffitt Cancer Center & Research Institute, Inc. (Moffitt Cancer Center) - Tampa
North Carolina
- Levine Cancer Institute - Charlotte
Oklahoma
- Stephenson Cancer Center - Oklahoma City
Pennsylvania
- The University of Pennsylvania Health System - Philadelphia
Tennessee
- Tennessee Oncology, PLLC - Nashville
Texas
- The University of Texas, MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2016-12 |
| Est. Completion | 2020-04 |
| Phase | Phase 1 |
What the finished NCT03030287 record still lists
NCT03030287 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (27% lower).
The record links to 3 conditions, with Cancer Ovaries appearing as the primary indexed condition, and to 2 interventions - of which Paclitaxel is the first listed.
NCT03030287 lists 7 locations in 7 states (Colorado, Florida, North Carolina).
Frequently Asked Questions
What is clinical trial NCT03030287 about?
NCT03030287 is a clinical study titled "A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer". The purpose of this study is to test the efficacy and safety of an experimental drug, OMP-305B83, when given in combination with paclitaxel. OMP-305B83 is a humanized monoclonal antibody and was developed to target cancer stem cells. Based on preclinical studies, it is believed that OMP-305B83 may b...
What is the current status of trial NCT03030287?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2016-12. Estimated completion is 2020-04.
What conditions does trial NCT03030287 study?
This clinical trial studies the following conditions: Cancer Ovaries, Cancer Peritoneal, Cancer, Fallopian Tube.
What interventions are being tested in trial NCT03030287?
The interventions under investigation include: Paclitaxel (DRUG), OMP-305B83 (DRUG).
Who is sponsoring clinical trial NCT03030287?
This trial is sponsored by OncoMed Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03030287 being conducted?
This trial has 7 study locations across Colorado, Florida, North Carolina, Oklahoma, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03030287's enrollment target sits among peer trials
44 1086th of 2000 higher than 901 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia